Emergent BioSolutions Secures $21.5 Million US Defense Order and Advances Mpox Study
Emergent BioSolutions received a $21.5 million order from the US Department of War for its anthrax vaccine BioThrax, with deliveries through 2026. The company also announced a partnership with PANTHER for an Africa CDC-led Mpox treatment trial.